If You Invested in ChromaDex Corporation (CDXC)

ChromaDex Corp. (NASDAQ: CDXC), which is changing its corporate name to Niagen Bioscience, Inc. and its Nasdaq ticker symbol to NAGE, is a global bioscience company focused on the science of healthy aging. The company describes itself as the global authority on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme found in every cell of the human body and a key regulator of cellular metabolism. According to ChromaDex, NAD+ levels decline with age and exposure to everyday stressors, and this decline is associated with age-related changes in health and vitality.

ChromaDex’s business centers on researching, developing, and commercializing NAD+ precursors, particularly nicotinamide riboside chloride (NR or NRC), which it has commercialized as its flagship ingredient Niagen®. The company states that Niagen is available in both food-grade and pharmaceutical-grade forms and is protected, along with other NAD+ precursors, by its patent portfolio. ChromaDex positions Niagen as a clinically proven NAD+ booster and describes it as the most efficient and superior-quality NAD+ booster available, supported by numerous peer-reviewed human clinical studies.

Core products and brands

ChromaDex delivers Niagen as the sole or principal dietary ingredient in its consumer product line Tru Niagen®. Tru Niagen is described as a healthy-aging NAD+ supplement that is clinically proven to increase NAD+ levels and is presented by the company as the number one healthy-aging NAD+ supplement in the United States based on revenue data from a large U.S. e‑commerce marketplace over a specified period. Tru Niagen is sold directly to consumers and through partnerships with global retailers and distributors.

Beyond its direct-to-consumer supplements, ChromaDex develops and commercializes ingredient technologies based on Niagen. These include food-grade Niagen®, supplied as a raw material to manufacturers of consumer products, and pharmaceutical-grade Niagen®, supplied to U.S. FDA‑registered 503B outsourcing facilities. These facilities compound and distribute intravenous and injectable Niagen products, known as Niagen IV and Niagen injections, which are available exclusively at clinics with a prescription. The company has also described a broader Niagen Plus / Niagen+ product line featuring pharmaceutical-grade Niagen for wellness clinics.

ChromaDex further notes that it offers natural product fine chemicals, referred to as phytochemicals, along with related research and development services. Historically, the company has referenced additional nutraceutical ingredients, but its recent communications emphasize Niagen, Tru Niagen, and pharmaceutical-grade Niagen IV and injections as its primary commercial focus.

Scientific and research focus

The company highlights a research-driven model built around NAD+ biology. ChromaDex states that its team includes world‑renowned scientists who work with independent investigators at universities and research institutions around the world to uncover the full potential of NAD+. Through the ChromaDex External Research Program (CERP™), the company has entered into numerous research agreements and supported a large body of peer‑reviewed publications and human clinical studies on Niagen and NAD+ biology. ChromaDex characterizes itself as setting the benchmark for scientific rigor, safety, quality, and transparency in NAD+ research and supplementation.

According to its public statements, ChromaDex’s scientific work has also extended into regulatory and clinical development pathways. The company reports that nicotinamide riboside (NR) has received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the potential treatment of Ataxia Telangiectasia (AT), a rare, progressive childhood disorder affecting neurological and immune function. ChromaDex has indicated that it is actively engaged with the FDA to address regulatory considerations and advance an Investigational New Drug (IND) application related to NR for AT.

Business model and revenue drivers

Based on its disclosures, ChromaDex generates revenue from several related activities built around Niagen and NAD+ science:

• Direct-to-consumer supplements: Sales of Tru Niagen, where Niagen is the primary active ingredient.
• Ingredient sales: Supply of food-grade Niagen to manufacturers of consumer products that incorporate NAD+ precursors.
• Pharmaceutical-grade Niagen: Supply of Niagen to FDA‑registered 503B outsourcing facilities, which compound Niagen IV and Niagen injections for use in clinics, including wellness-focused clinics.
• Collaborations and partnerships: Inclusion of Niagen as a key ingredient in third‑party longevity and healthy‑aging supplements, such as formulations launched by longevity‑focused organizations.
• Fine chemicals and R&D services: Sales of phytochemicals and provision of related research and development services.

ChromaDex has also reported that its Niagen IV product has been rolled out across a large network of wellness clinics in the United States through its pharmaceutical-grade Niagen supply chain. The company has described Niagen IV as a significant advancement in intravenous NAD+ therapy, citing a pilot clinical study in which Niagen IV demonstrated shorter infusion times and a measurable increase in whole blood NAD+ levels compared to NAD+ IV.

Corporate evolution and ticker transition

ChromaDex’s shares have traded on the Nasdaq under the ticker symbol CDXC. The company has announced that it will change its corporate name to Niagen Bioscience, Inc. and that its common stock will begin trading under the new Nasdaq symbol NAGE on a specified effective date. The company has stated that no action is required by existing shareholders in connection with this ticker symbol change and that its common stock will continue to be listed on Nasdaq, with the CUSIP remaining unchanged.

For investors and observers, the CDXC symbol therefore represents the historical trading symbol associated with ChromaDex’s development into a NAD+‑focused bioscience and nutraceutical company and its subsequent rebranding toward Niagen Bioscience. The announced change reflects the central role of Niagen and NAD+ science in the company’s identity and operations.

Position within the healthy aging and NAD+ space

Within the broader healthy aging and nutraceutical landscape, ChromaDex emphasizes its specialization in NAD+ research and NAD+ precursor ingredients. The company repeatedly describes itself as the global authority on NAD+ and highlights Niagen as its clinically proven flagship ingredient. Through Tru Niagen, Niagen IV, Niagen injections, and partnerships with wellness clinics and longevity‑focused organizations, ChromaDex presents a unified strategy centered on supporting cellular health and healthy aging via NAD+ replenishment.

ChromaDex also underscores its focus on quality and regulatory oversight, noting that its pharmaceutical-grade Niagen products are compounded and distributed by U.S. FDA‑registered 503B outsourcing facilities, and that its NAD+ precursor ingredients are protected by a robust patent portfolio. The company’s communications indicate that it intends to continue investing in research and development to explore additional applications of NAD+ precursors, including rare disease indications such as Ataxia Telangiectasia.

Summary

In summary, ChromaDex Corp. (CDXC)—transitioning to Niagen Bioscience, Inc. (NAGE)—is a bioscience and nutraceutical company focused on NAD+ biology and healthy aging. Its core activities include the development and commercialization of Niagen as a dietary ingredient and pharmaceutical-grade product, the sale of Tru Niagen supplements, the supply of Niagen IV and injections through clinical channels, and the support of extensive external research on NAD+ and Niagen. Investors researching CDXC can view it as the historical ticker associated with this NAD+‑centric business model and its evolution toward the Niagen Bioscience identity.